The expiry of patents on profitable heart medicines is soon going to erode one of the main sources of drug company profits, and risky bets on new medicines to replace them may not make up for the lost sales
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment